A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder

David Mischoulon, Catherine Best-Popescu, Michael Laposata, Wendelien Merens, Jessica L. Murakami, Shirley L. Wu, George I. Papakostas, Christina M. Dording, Shamsah B. Sonawalla, Andrew A. Nierenberg, Jonathan E. Alpert, Maurizio Fava

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

We examined the antidepressant efficacy and dose-response pattern of the n-3 docosahexaenoic acid (DHA). Thirty-five depressed adult outpatients (46% women; mean age 42 ± 14 years) with a 17-item Hamilton-Depression Scale (HAM-D-17) score of > /= 18 were randomized into one of three double-blind dosing arms for 12 weeks. Group A (n = 14): 1 g/day of oral DHA; Group B (n = 11): 2 g/day; and Group C (n = 10): 4 g/day. We measured HAM-D-17 scores, plasma DHA, eicosapentaenoic acid (EPA), and n-6/n-3 ratio. Completer response rates (> /= 50% decrease in HAM-D-17 score) were 83% for Group A, 40% for Group B, and 0% for Group C; Groups A and B had significant decreases in HAM-D-17 scores (p < 0.05). For completers and intent-to-treat subjects, plasma DHA increased significantly (p < 0.05), EPA had little change (p > 0.05), and n-6/n-3 decreased significantly (p < 0.05). DHA may be effective for depression at lower doses.

Original languageEnglish (US)
Pages (from-to)639-645
Number of pages7
JournalEuropean Neuropsychopharmacology
Volume18
Issue number9
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

Docosahexaenoic Acids
Major Depressive Disorder
Depression
Eicosapentaenoic Acid
Antidepressive Agents
Outpatients

Keywords

  • Depression
  • DHA
  • Docosahexaenoic acid
  • Eicosapentaenoic acid
  • EPA
  • n-3
  • Omega-3

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. / Mischoulon, David; Best-Popescu, Catherine; Laposata, Michael; Merens, Wendelien; Murakami, Jessica L.; Wu, Shirley L.; Papakostas, George I.; Dording, Christina M.; Sonawalla, Shamsah B.; Nierenberg, Andrew A.; Alpert, Jonathan E.; Fava, Maurizio.

In: European Neuropsychopharmacology, Vol. 18, No. 9, 09.2008, p. 639-645.

Research output: Contribution to journalArticle

Mischoulon, D, Best-Popescu, C, Laposata, M, Merens, W, Murakami, JL, Wu, SL, Papakostas, GI, Dording, CM, Sonawalla, SB, Nierenberg, AA, Alpert, JE & Fava, M 2008, 'A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder', European Neuropsychopharmacology, vol. 18, no. 9, pp. 639-645. https://doi.org/10.1016/j.euroneuro.2008.04.011
Mischoulon, David ; Best-Popescu, Catherine ; Laposata, Michael ; Merens, Wendelien ; Murakami, Jessica L. ; Wu, Shirley L. ; Papakostas, George I. ; Dording, Christina M. ; Sonawalla, Shamsah B. ; Nierenberg, Andrew A. ; Alpert, Jonathan E. ; Fava, Maurizio. / A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. In: European Neuropsychopharmacology. 2008 ; Vol. 18, No. 9. pp. 639-645.
@article{bef4c24933ed49a4be48888289986be9,
title = "A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder",
abstract = "We examined the antidepressant efficacy and dose-response pattern of the n-3 docosahexaenoic acid (DHA). Thirty-five depressed adult outpatients (46{\%} women; mean age 42 ± 14 years) with a 17-item Hamilton-Depression Scale (HAM-D-17) score of > /= 18 were randomized into one of three double-blind dosing arms for 12 weeks. Group A (n = 14): 1 g/day of oral DHA; Group B (n = 11): 2 g/day; and Group C (n = 10): 4 g/day. We measured HAM-D-17 scores, plasma DHA, eicosapentaenoic acid (EPA), and n-6/n-3 ratio. Completer response rates (> /= 50{\%} decrease in HAM-D-17 score) were 83{\%} for Group A, 40{\%} for Group B, and 0{\%} for Group C; Groups A and B had significant decreases in HAM-D-17 scores (p < 0.05). For completers and intent-to-treat subjects, plasma DHA increased significantly (p < 0.05), EPA had little change (p > 0.05), and n-6/n-3 decreased significantly (p < 0.05). DHA may be effective for depression at lower doses.",
keywords = "Depression, DHA, Docosahexaenoic acid, Eicosapentaenoic acid, EPA, n-3, Omega-3",
author = "David Mischoulon and Catherine Best-Popescu and Michael Laposata and Wendelien Merens and Murakami, {Jessica L.} and Wu, {Shirley L.} and Papakostas, {George I.} and Dording, {Christina M.} and Sonawalla, {Shamsah B.} and Nierenberg, {Andrew A.} and Alpert, {Jonathan E.} and Maurizio Fava",
year = "2008",
month = "9",
doi = "10.1016/j.euroneuro.2008.04.011",
language = "English (US)",
volume = "18",
pages = "639--645",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder

AU - Mischoulon, David

AU - Best-Popescu, Catherine

AU - Laposata, Michael

AU - Merens, Wendelien

AU - Murakami, Jessica L.

AU - Wu, Shirley L.

AU - Papakostas, George I.

AU - Dording, Christina M.

AU - Sonawalla, Shamsah B.

AU - Nierenberg, Andrew A.

AU - Alpert, Jonathan E.

AU - Fava, Maurizio

PY - 2008/9

Y1 - 2008/9

N2 - We examined the antidepressant efficacy and dose-response pattern of the n-3 docosahexaenoic acid (DHA). Thirty-five depressed adult outpatients (46% women; mean age 42 ± 14 years) with a 17-item Hamilton-Depression Scale (HAM-D-17) score of > /= 18 were randomized into one of three double-blind dosing arms for 12 weeks. Group A (n = 14): 1 g/day of oral DHA; Group B (n = 11): 2 g/day; and Group C (n = 10): 4 g/day. We measured HAM-D-17 scores, plasma DHA, eicosapentaenoic acid (EPA), and n-6/n-3 ratio. Completer response rates (> /= 50% decrease in HAM-D-17 score) were 83% for Group A, 40% for Group B, and 0% for Group C; Groups A and B had significant decreases in HAM-D-17 scores (p < 0.05). For completers and intent-to-treat subjects, plasma DHA increased significantly (p < 0.05), EPA had little change (p > 0.05), and n-6/n-3 decreased significantly (p < 0.05). DHA may be effective for depression at lower doses.

AB - We examined the antidepressant efficacy and dose-response pattern of the n-3 docosahexaenoic acid (DHA). Thirty-five depressed adult outpatients (46% women; mean age 42 ± 14 years) with a 17-item Hamilton-Depression Scale (HAM-D-17) score of > /= 18 were randomized into one of three double-blind dosing arms for 12 weeks. Group A (n = 14): 1 g/day of oral DHA; Group B (n = 11): 2 g/day; and Group C (n = 10): 4 g/day. We measured HAM-D-17 scores, plasma DHA, eicosapentaenoic acid (EPA), and n-6/n-3 ratio. Completer response rates (> /= 50% decrease in HAM-D-17 score) were 83% for Group A, 40% for Group B, and 0% for Group C; Groups A and B had significant decreases in HAM-D-17 scores (p < 0.05). For completers and intent-to-treat subjects, plasma DHA increased significantly (p < 0.05), EPA had little change (p > 0.05), and n-6/n-3 decreased significantly (p < 0.05). DHA may be effective for depression at lower doses.

KW - Depression

KW - DHA

KW - Docosahexaenoic acid

KW - Eicosapentaenoic acid

KW - EPA

KW - n-3

KW - Omega-3

UR - http://www.scopus.com/inward/record.url?scp=48749130377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48749130377&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2008.04.011

DO - 10.1016/j.euroneuro.2008.04.011

M3 - Article

VL - 18

SP - 639

EP - 645

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 9

ER -